Literature DB >> 1904312

Ovarian cancer: new clinical approaches.

R F Ozols1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1904312     DOI： 10.1016/0305-7372(91)90027-w

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  16 in total

1.  Determination of hypersensitivity to genotoxic agents among Escherichia coli single gene knockout mutants.

Authors:  Elinne Becket; Frank Chen; Cindy Tamae; Jeffrey H Miller
Journal:  DNA Repair (Amst)       Date:  2010-07-31

2.  The interactions of the ruthenium(II)-cymene complexes with lysozyme and cytochrome c.

Authors:  Dragana Stanic-Vucinic; Stefan Nikolic; Katarina Vlajic; Mirjana Radomirovic; Jelena Mihailovic; Tanja Cirkovic Velickovic; Sanja Grguric-Sipka
Journal:  J Biol Inorg Chem       Date:  2020-02-04       Impact factor: 3.358

Review 3.  p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.

Authors:  Valentina Grossi; Alessia Peserico; Tugsan Tezil; Cristiano Simone
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.

Authors:  Stephen Shang; Jiekun Yang; Amir A Jazaeri; Alexander James Duval; Turan Tufan; Natasha Lopes Fischer; Mouadh Benamar; Fadila Guessous; Inyoung Lee; Robert M Campbell; Philip J Ebert; Tarek Abbas; Charles N Landen; Analisa Difeo; Peter C Scacheri; Mazhar Adli
Journal:  Cancer Res       Date:  2019-07-29       Impact factor: 12.701

5.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; G Abel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression.

Authors:  Neal R Godse; Nayel Khan; Zachary A Yochum; Roberto Gomez-Casal; Carolyn Kemp; Daniel J Shiwarski; Raja S Seethala; Scott Kulich; Mukund Seshadri; Timothy F Burns; Umamaheswar Duvvuri
Journal:  Clin Cancer Res       Date:  2017-09-12       Impact factor: 12.531

Review 7.  New platinum agents. A comparison in ovarian cancer.

Authors:  L R Kelland; M J McKeage
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

8.  DNA damage-binding complex recruits HDAC1 to repress Bcl-2 transcription in human ovarian cancer cells.

Authors:  Ran Zhao; Chunhua Han; Eric Eisenhauer; John Kroger; Weiqiang Zhao; Jianhua Yu; Karuppaiyah Selvendiran; Xingluo Liu; Altaf A Wani; Qi-En Wang
Journal:  Mol Cancer Res       Date:  2013-11-18       Impact factor: 5.852

9.  Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell.

Authors:  Wei Yu; Chengmeng Jin; Xiaoyan Lou; Xu Han; Lisha Li; Yinghua He; Hongyu Zhang; Kelong Ma; Jingde Zhu; Lihua Cheng; Biaoyang Lin
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

10.  Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.

Authors:  Martin P Barr; Steven G Gray; Andreas C Hoffmann; Ralf A Hilger; Juergen Thomale; John D O'Flaherty; Dean A Fennell; Derek Richard; John J O'Leary; Kenneth J O'Byrne
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.